News - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

226 to 250 of 2120 results

Molecular nano-spies created to aid disease detection

Molecular nano-spies created to aid disease detection

14-01-2014

Stealth nano compounds have been designed by researchers at the UK’s University of Nottingham’s School…

BiotechnologyResearchUK

Agenus to acquire Switzerland’s 4-Antibody AG

14-01-2014

US biotech firm Agenus has entered into a definitive agreement to acquire 4-Antibody AG, a private Switzerland-headquartered…

4-Antibody AGAgenusBiotechnologyGITRMergers & AcquisitionsOncologyOX40

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa

13-01-2014

UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Cell Therapeutics to reacquire rights to two anti-cancer compounds

13-01-2014

US biotech firm Cell Therapeutics says it has reached an agreement with partner Novartis to reacquire…

BiotechnologyCell TherapeuticsLicensingNovartisOncologyOpaxioPixuvri

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Regeneron amends investor agreement with Sanofi

Regeneron amends investor agreement with Sanofi

13-01-2014

US biotech firm Regeneron Pharmaceuticals says it has amended and restated its investor agreement with…

BiotechnologyMergers & AcquisitionsRegeneronSanofi

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Pharma M&A deals in 2013 down, but values marginally higher

Pharma M&A deals in 2013 down, but values marginally higher

13-01-2014

Merger and acquisition activity in the pharmaceutical, biotechnology and generic drugs sectors continued…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Alnylam to acquire Merck’s Sirna Therapeutics

Alnylam to acquire Merck’s Sirna Therapeutics

13-01-2014

US RNAi therapeutics specialist Alnylam Pharmaceuticals says it has reached agreement to acquire US pharma…

Alnylam PharmaceuticalsBiotechnologyMerck & CoMergers & AcquisitionsSirna Therapeutics

Mersana Therapeutics reaches second preclinical milestone in Endo collaboration

10-01-2014

Privately-held US biotech company Mersana Therapeutics has achieved its second preclinical milestone…

BiotechnologyEndo PharmaceuticalsFinancialLicensingMersanaOncologyResearchUSA

Nuevolution signs licensing agreement with Novartis

Nuevolution signs licensing agreement with Novartis

10-01-2014

Denmark-based Nuevolution has entered into a non-exclusive technology licensing agreement with Swiss…

BiotechnologyDenmarkGeneticsLicensingNorthern EuropeNovartisNuevolutionResearch

US drug approvals lower than previously reported; new study

10-01-2014

The overall success rate for drugs moving through clinical trials to US Food and Drug Administration…

BiotechnologyNorth AmericaPharmaceuticalRegulationResearchUSA

Tracleer “whistleblower” case by the US Department of Justice dismissed

Tracleer “whistleblower” case by the US Department of Justice dismissed

10-01-2014

In connection with a qui tam proceeding ("whistleblower case"), Swiss biotech firm Actelion previously…

ActelionBiotechnologyLegalNorth AmericaRespiratory and PulmonaryTracleerUSA

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

10-01-2014

US biotech firm Biogen Idec and Sangamo Biosciences have signed an exclusive worldwide collaboration…

Biogen IdecBiotechnologyHematologyLicensingResearchSangamo BioSciences

CytomX and ImmunoGen announce collaboration to develop Probody-Drug Conjugates against cancer targets

09-01-2014

US biotech firms CytomX Therapeutics and ImmunoGen (Nasdaq: IMGN) have signed a collaboration agreement…

BiotechnologyCytomX TherapeuticsImmunoGenLicensingOncologyResearchUSA

Seattle Genetics expands cancer drug collaboration with AbbVie

Seattle Genetics expands cancer drug collaboration with AbbVie

09-01-2014

US biotech firm Seattle Genetics says it has further expanded its antibody-drug conjugate (ADC) collaboration…

AbbVieBiotechnologyLicensingOncologySeattle Genetics

Whooping cough vaccine agreement signed by ILiAD

09-01-2014

US biotech company ILiAD Biotechnologies has signed scientific collaboration and worldwide license agreements…

BiotechnologyFranceILiAD BiotechnologiesLicensingResearchRespiratory and PulmonaryUSA

Merck Serono appoints Steven Hildemann as global chief medical officer

Merck Serono appoints Steven Hildemann as global chief medical officer

09-01-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA (MRK: DE), has named Steven Hildemann as global…

BiotechnologyBoardroomGermanyMerck Serono

J&J Innovation expands presence to Israel; announces early-stage deals

J&J Innovation expands presence to Israel; announces early-stage deals

08-01-2014

Through its Johnson & Johnson Innovation unit, health care giant Johnson & Johnson is expanding its global…

Assembly PharmaceuticalsBiocerosBiotechnologyJohnson & JohnsonNodalityPharmaceuticalScholar RockSutroVaxTopiVert

Nanomedicines market to reach $177.6 billion globally in 2019

08-01-2014

The global market for nanomedicine was valued at $78.54 billion in 2012 and is expected to reach a value…

BiotechnologyCardio-vascularGlobalMarkets & MarketingOncology

Promedior appoints William Hodder as vice president of business development

08-01-2014

US biotech company Promedior has announced that industry veteran William Hodder has joined the company…

BiotechnologyBoardroomPromediorUSA

Epizyme shares soar as Celgene deal triggers $25 million milestone payment

Epizyme shares soar as Celgene deal triggers $25 million milestone payment

08-01-2014

US biotech company Epizyme has announced the achievement of the proof of concept milestone in the EPZ-5676…

BiotechnologyCelgeneEpizymeFinancialOncologyResearchUSA

Neurocrine rockets on positive Phase II data for tardive dyskinesia treatment

08-01-2014

Shares of Neurocrine Biosciences were up almost 80% yesterday after it announced that NBI-98854, a small…

BiotechnologyNeurocrine BiosciencesNeurologicalResearchUSA

226 to 250 of 2120 results

Back to top